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Background: Total joint replacement (TJR) procedures have been one of the most rewarding interventions for
treating patients suffering from joint disease. However, developing a periprosthetic joint infection (PJI) is a serious
complication that is associated with the highest burden of cost and reduction in patients’ quality of life compared
to other complications following TJRs. One of the main challenges facing clinicians who are treating PJIs is accurately
diagnosing infection in a timely fashion. Multiple orthopedic associations have published clinical guidelines for
diagnosing PJI which are based solely on consensus approaches, expert opinions, and narrative reviews. We
believe that a higher quality of scientific rigor is necessary to establish a diagnostic guideline that represents
current evidence more accurately and that identifies important knowledge gaps in PJI diagnosis. Therefore, we
will conduct a systematic review on diagnostic performance of blood markers, synovial fluids, and tissue tests for
diagnosing PJI.
Methods/design: Electronic search strategies will be developed and tested by an experienced medical information
specialist in consultation with the review team, and gray literature will be searched using the checklist from CADTH’s
Grey Matters Light. Two reviewers will independently screen the literature for inclusion using the prespecified eligibility
criteria. Non-English language and animal-only studies will be excluded. Quality assessment and data extractions by
reviewers will be verified, and disagreements will be resolved through consensus or third party adjudication. We will
assess the quality of individual studies using the QUADAS-2 tool and use GRADE to summarize the strength of
body of evidence. Analyses of evidence will be conducted in accordance with the Cochrane Handbook for
Diagnostic Test Accuracy Reviews.
Discussion: We will conduct a systemic review of tests (blood markers, synovial fluids, and tissue testing) for
diagnosing PJI in patients’ knee, hip, and shoulder joint replacements. This will be the first scientifically rigorous
and comprehensive systematic review in the field and may feed into an evidence-based clinical practice guideline. We
will compare the findings of this review with the consensus-based guides and discuss the differences, similarities, and
knowledge gaps.
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Total joint replacement (TJR) procedures have been one
of the most rewarding interventions for treating patients
suffering from joint disease. However, developing a peri-
prosthetic joint infection (PJI) is a serious complication
that is associated with the highest burden of cost and
reduction in patients’ quality of life when compared to
other complications following TJRs [1]. One of the main
challenges facing clinicians who are treating PJIs is ac-
curately diagnosing infection in a timely fashion. Mul-
tiple orthopedic associations have published clinical
guidelines for diagnosing PJI which are based solely on
consensus approaches, expert opinions, and narrative
reviews [2–5]. Furthermore, they fail to cover all types
of prosthetic joints.
The average rate of PJI within 2 years after primary
TJR is estimated at 2.0 %, but can reach as high as 14 %
in revision TJR surgeries [6]. The current process of
diagnosing and treating PJIs incurs a substantial clinical
and economic burden for surgeons, hospitals, and most
importantly, patients [7]. Based on an economic analysis
by Kurtz et al. [8], the annual cost to US hospitals of
treating PJIs has increased from $320 million to $566
million over the span of 8 years and is projected to ex-
ceed $1.62 billion by 2020. Establishing an accurate and
a timely diagnosis of PJI is a key step toward implement-
ing an effective treatment. An earlier diagnosis with an
associated surgical intervention does lead to improve
survivorship of the implants (i.e., no recurrence of infec-
tion and preservation of the original implants thus sig-
nificantly reducing the morbidity and cost). Additionally,
late diagnosis of PJI results in biofilm formation by the
infecting organism. This biofilm coats the whole implant
surface which necessitates the extraction of the whole
implant in order to eradicate the infection. This procedure
is very morbid and costly. The development of biofilm
also makes the infecting organism resistant to antibiotic
therapy. Biofilm formation starts within the first 2 weeks
of infection symptoms; therefore, establishing and early
diagnosis of PJI is critical to improve patient’s outcome
and response to therapy [9, 10]. We can improve the qual-
ity of care delivered to patients suffering from PJI by
translating the knowledge synthesized from this systematic
review into evidence-based recommendations that can
guide clinicians and surgeons in accurately and quickly
diagnosing PJI. These recommendations also constitute
the cornerstone for further research to fill the knowledge
gaps identified in PJI diagnosis.
Patients who develop PJIs are predisposed to multiple
surgeries that can lead to the loss of their life or limb
and result in longer than average lengths of stay in the
hospital. A major clinical challenge in successfully treat-
ing PJI is the current lack of “gold standard” diagnostic
tests or protocols for accurately diagnosing infection ina timely fashion. To date, there are two main tests pro-
posed as gold standard by recent guidelines for assisting
clinicians in their diagnosis of PJI: sampling synovial
fluid or tissue to assess the prevalence of neutrophils and
culturing the offending organism, and testing serum levels
of C-reactive protein (CRP) and erythrocyte sedimentation
rate (ESR). Having said that, the sensitivity of synovial fluid
culture is challenged by the so-called culture-negative infec-
tions. Currently, there are no clear clinical pathways to
diagnose PJI and to describe when and how these diagnos-
tic tests should be used. The current status is the presence
of few consensus guidelines that recommend the use of
blood markers, synovial fluid, and tissue testing to guide
the clinician in diagnosing PJI. However, these current
guidelines lack the evidence of indicating how these tests
should be triaged and added on or used to replace an exist-
ing test [2–5]. We believe that this systematic review can
help address this gap by identifying the true evidence sup-
porting the diagnostic performance of each candidate test
chosen. These results will help guide clinicians to develop a
clear clinical pathway for the use of these tests based on
evidence. The eventual purpose of these tests is to rule out
infection and/or confirm infection and not to identify those
at risk of developing a PJI. As such, these markers as stand-
alone tests would be optimal.
Numerous studies have shown that these diagnostic
tests are limited in their accuracy [11]. Although syn-
ovial or tissue cultures yield 95–100 % specificity, they
have poor sensitivity of only 56–75 % [12]. The CRP
and ESR are non-specific markers of inflammation and
therefore are not reliable during the first 3 weeks of the
postoperative period or in the event of other inflammatory
conditions such as rheumatoid arthritis.
The literature reports over 20 additional diagnostic tests
developed to improve the sensitivity of detecting early
signs of PJI [13–20]. These investigations are diverse but
fall into four main categories of testing, namely, serum,
synovial fluid, synovial tissue, and nuclear imaging.
Studies that describe the benefits of these tests are het-
erogeneous in their designs and recommendations which
limits their clinical applicability. Additionally, numerous
guidelines published for diagnosing PJI are based solely
on consensus approaches, expert opinions, and narrative
reviews [2–5]. In addition, some of these new biomarker
tests are more expensive and not readily available in most
laboratories. We believe that a higher quality of scientific
rigor is necessary to establish a diagnostic guideline that
represents current evidence more accurately and that
identifies important knowledge gaps in diagnosing PJI.
Therefore, we propose a research question: “what is the
current evidence for the accurate diagnosis of PJIs using
published protocols that support the use of blood markers,
synovial fluid and tissue testing as diagnostic tools?” Our
objective is to conduct a systematic review that can assess
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nostic tests available for PJI. Nuclear imaging, however,
will be excluded from the protocol because the test, al-
though highly sensitive, is shown to be non-specific with
consequently moderate to poor reliability [21, 22].
The goal of this review is to generate new quantitative
evidence for clinicians and guideline developers to estab-
lish evidence-based guidelines for diagnosing PJI. Ultim-
ately, this will improve the management of patients with
PJI, as effective treatment of PJI requires accurate and
quick diagnosis.
Methods/design
The methodological approach to evidence searching and
synthesis, as described in this protocol, will conform to
the Cochrane Collaboration’s diagnostic test accuracy
methods [23]. Our approach consists of performing a
literature search, screening the studies identified, and
selecting the studies that meet the eligibility criteria.
We will extract the data from the selected studies, assess
their methodological quality, and perform a GRADE
assessment on the body of evidence. Other activities
will include statistical analyses, evidence synthesis, and
report compilation that will be carried out in chronological
order as outlined in the steps below. We will adhere to
standards of the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) in reporting the
findings of this review [24]. The content of this protocol
follows the Preferred Reporting Items for Systematic
Review and Meta-Analysis Protocols (PRISMA-P) rec-
ommendations [25]. (Please see Additional file 1 for
PRISMA-P detailed checklist.) This review is registered
with the International Prospective Register of Systematic
Reviews (PROSPERO) [26]. The registration number is
CRD42015023768.
Eligibility criteria
Table 1 presents the detailed eligibility criteria for this
review. English language studies and studies with all sex-
and gender-eligible (post-arthroplasty) populations report-
ing data from disease (PJI) of the hip, knee, and shoulder
that investigated one of the candidate laboratory tests (see
below) will be included. Therefore, animal-only studies
and studies that do not report data on diagnostic perform-
ance of candidate index tests against the clinical reference
standard will be excluded or removed.
Literature search
Electronic search strategies will be developed and tested
by an experienced medical information specialist in con-
sultation with the review team (please see search strat-
egy in Additional file 2) [27]. Using the OVID platform,
we will search Ovid MEDLINE®, MEDLINE® In-Process
& Other Non-Indexed Citations, and Embase. Using theCochrane Library on Wiley (including Cochrane), we will
search the following: Database of Systematic Reviews,
DARE, CENTRAL, HTA, and NHS EED. Vocabulary and
syntax will be adjusted across databases.
Strategies will utilize a combination of controlled
vocabulary (e.g., “prosthesis-related infections,” “joint
prosthesis/adverse effects,” “arthritis, infectious/diagnosis”)
and keywords (e.g., “periprosthetic joint infection,” “replace-
ment joint infection,” “PJI”). When possible, animal-only
studies and opinion pieces will be removed.
We will perform a search for gray literature using
CADTH’s Grey Matters Light [28]. Additional references
will be sought through hand-searching the bibliographies
of relevant studies.
Study screening and selection
Screening will be performed by uploading citations into
an online systematic review software program (Distiller
Systematic Review (DSR) Software©) [29] and will in-
volve a two-step process:
– Step 1: title/abstract screening
– Step 2: full-text screening
At both levels, eligibility will be determined independ-
ently by two reviewers. Initial piloting will involve 20–25
citations as training dataset to reach acceptable levels of
agreement between the reviewers.
Disagreements among reviewers will be resolved through
consensus or third party adjudication. Reports that are
duplicates or co-publications of studies will be identified.
Following full-text screening, a list of excluded studies
with reasons for exclusion will be provided in an appendix
of the final report.
We will begin with screening published and unpublished
records and select those that meet inclusion/exclusion cri-
teria. Our search of literature will involve both primary
studies and systematic reviews. The latter will be used as
an additional source of primary studies.
It is understood that the full literature search may un-
cover novel biomarkers and these will be included if the
studies meet the other criteria.
Data extraction
We will develop data extraction forms and pilot test on
a sample of studies to achieve acceptable levels of agree-
ment between the two data extractors. At a minimum,
the following information will be extracted with add-
itional data elements being added as deemed appropriate
during the review process:
– Study characteristics: author, year of publication,
country, design, sample size, clinical setting, joints
affected, duration of follow-up, number studied (or
Table 1 The review eligibility criteria
Study characteristics Inclusion criteria Exclusion criteria
Population Patients who have undergone knee, hip, and
shoulder joint replacements (no time frame as
infections may be chronic)
Patients who have undergone joint replacements
for other joints; and studies that use animal testing
Index tests
(intervention tests)
Blood markers, synovial tests, and tissue culture tests: Imaging tests
Blood markers
• Serum C-reactive protein (CRP)
• Serum erythrocyte sedimentation rate (ESR)
• Blood culture
• Serum white blood cell (WBC) count
• Serum interleukin-6 (IL-6) levels
• Serum procalcitonin levels
• Serum interferon-alpha levels
• Serum toll-like receptor 2 (TLR2)
• Human beta-defensin-3 levels
• Neutrophil CD64
• Soluble intercellular adhesion molecule-1 (sICAM-1)
• Tumor necrosis factor-alpha (TNF-alpha)
• Neutrophil elastase 2 (ELA-2)
• Bactericidal/permeability-increasing protein
• Neutrophil gelatinase-associated lipocalin
• Lactoferrin (LF)
Synovial fluid tests:
• Synovial fluid white blood cell (WBC) count; Synovial
fluid polymorphonuclear neutrophil percentage (PMN%) analysis
• Synovial C-reactive protein (CRP) levels
• Synovial neutrophil-derived circulating free DNA/neutrophil
extracellular traps (cf-DNA/NETS)
• Intra-articular purulence
• Application of synovial fluid to leukocyte esterase test strip
• α-defensin
Tissue tests:
• Periprosthetic tissue culture/swab culture/joint aspiration culture
• Histological analysis: PMN per high power field
• Gram stain
• Routine acid-fast bacillus (AFB) testing and fungal testing
• Polymerase chain reaction (PCR) and molecular techniques
Note on how the above tests were selected: We first selected the
three main diagnostic categories that are considered to be important
in identifying PJI (blood markers, synovial fluid tests, and tissue tests).
Under each major category, we chose the tests that are routinely used
and are considered part of good clinical practice such as ESR, CRP, and
tissue cultures. We have also included new diagnostic tests, such as alpha-
defensin and leukocyte esterase strips, that have been recently published
and described as novel tests that can overcome some of the limitation
of the routine tests.
Reference test
(comparator test)
Joint fluid (with cell count, gram stain, and culture) or tissue (with
histopathology and culture)
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Table 1 The review eligibility criteria (Continued)
Note: given the lack of gold standard for diagnosing PJI, we
will also consider any gold standard used in the primary studies
and consult our clinical experts to accurately classify them.
Outcomes • Sensitivity and specificity of individual tests Studies that do not investigate diagnostic
performance of the index tests
• Negative predictive value (NPV) and positive predictive value (PPV)
• Positive likelihood ratio (LR+) and negative likelihood ratio (LR−)
Study designs We will include randomized controlled trials, cross-sectional,
systematic reviews, controlled cohort, and case-control studies
(recognizing that the latter may overestimate test performance) [37–39].
Case reports, commentaries, expert opinion,
and narrative reviews
Index tests in italic font are the tests prioritized as the primary tests that we will use to assess their diagnostic accuracy performance. The rest of the index tests
are considered as secondary to our analyses, and depending on the amount of literature and work load, it may or may not fall under the scope of this review to
assess their diagnostic accuracy performance. Table 1 presents the eligibility criteria (inclusion and exclusion), particularly population, index tests, reference test,
and outcomes of interest for this systematic review
α alpha, AFB acid-fast bacillus, Cf-DNA circulating free DNA, CD64 cluster of differentiation 64, CRP C-reactive protein, DNA deoxyribonucleic acid, ESR erythrocyte
sedimentation rate, ELA-2 elastase 2, IL-6 interleukin-6, LF lactoferrin, LR+ positive likelihood ratio, LR− negative likelihood ratio, NETs neutrophil extracellular traps,
NPV negative predictive value, PMN% polymorphonuclear neutrophil percentage, PCR polymerase chain reaction, PPV positive predictive value, sICAM-1 soluble
intercellular adhesion molecule-1, TLR2 toll-like receptor 2, TNF-alpha tumor necrosis factor-alpha, WBC white blood cell count
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analyzed for each outcome, number of drop-outs
with reason, and funding source.
– Population characteristics: inclusion/exclusion
criteria; patient characteristics such as mean age,
race, sex, BMI, and history of joint arthroplasty or
previous surgery; surgical-related characteristics such
as surgeon and hospital volume, joint (knee, hip,
shoulder), operative time, previous procedure in
operating room, anesthetic management, postoperative
risk factors prior to discharge (e.g., persistent
postoperative wound drainage, distant infection,
and length of stay), postdischarge (e.g., dental work,
subsequent surgery), and time since prosthesis
implantation.
– Intervention characteristics: timing of sampling;
method of sampling (e.g., location of swab), method
of measuring, threshold, frequency, and subsequent
management.
– Gold standard: To the best of our knowledge, there
is no generally accepted gold standard, so we will be
guided by those used in published studies. These
seem to include simple standard culture of joint
aspirate, prolonged culture of sonicated biofilm or
explanted prosthesis, and final adjudication of cases
by an expert panel after full follow-up. We will work
with our knowledge users (orthopedic surgeons and
infectious disease specialists) to categorize the likely
accuracy of the gold standards used by investigators
and determine what impact these have on measures
of diagnostic test performance.
– Outcomes: definitions of outcomes of review
interest, outcomes data (e.g., false/true positive,
false/true negative from 2 × 2 table for diagnostic
studies), sensitivity and specificity, negative
predictive value (NPV) and positive predictive value
(PPV), and positive likelihood ratio (LR+) andnegative likelihood ratio (LR−). Data will be
extracted by a single reviewer with all outcomes
data verified by a second reviewer. For each test/
marker, information will be summarized and
presented in an evidence table and summary of
findings table.Quality appraisal
We will assess the quality of the included studies of
diagnostic test accuracy using the QUADAS-2 tool [29].
Risk of bias assessments will be done by one reviewer,
with another reviewer providing verification to all of the
assessed studies. Based on the QUADAS-2 guidance, we
will tailor the tool according to our research question
(please see Additional file 3 and Additional file 4 for
further details).The Grading of Recommendations Assessment,
Development and Evaluation (GRADE)
If we find a sufficiently comprehensive literature for some
of the candidate tests, we will attempt to apply the GRADE
methodology to rate the quality of the body of evidence as
high, moderate, low, or very low [30]. Although GRADE
may have not been extensively used in diagnostic accuracy
reviews and the Cochrane collaboration may have not yet
officially recommended its use for such reviews, we will at-
tempt piloting incorporation of GRADE in this review. We
will create a summary of evidence table using the Grade
Development Tool [31]. To arrive at a rating, two reviewers
will independently assess the body of evidence for each
gradable outcome according to risk of bias, consistency,
directness, precision, and study design [32, 33]. Quality of
evidence will be judged for estimates of test performance
(true positive (TP), false positive (FP), true negative (TN),
and false negative (FN)) using previously published GRADE
guidance [32].
Beaule et al. Systematic Reviews  (2015) 4:148 Page 6 of 8Statistical analyses and evidence synthesis
Where data allow, each individual index test will be
compared against a reference test (gold standard—see
above). For each marker/test, TP, TN, FP, and FN will be
retrieved. Where authors do not report those values but
provide the raw data, we will calculate the values consider-
ing high sensitivity (95 %) for prioritized blood markers,
and high specificity (95 %) for prioritized synovial and
tissue tests. An evidence summary table will be re-
ported and each study will be presented in a forest plot.
The forest plot will display the data from the sensitivity
and specificity values of the marker test and the corre-
sponding 95 % confidence intervals. Heterogeneity that
may be explained by clinical or methodological differ-
ences between studies may preclude meta-analyses, as
will general sparsity of data or high risk of bias affecting
most or all of the relevant studies. If studies use a com-
mon threshold, then we will estimate summary sensitivity
and specificity.
For such analysis, we will use the bivariate model
(Reitsma [34]) which models the correlation between
sensitivity and specificity directly and assumes random
effects to account for the between study heterogeneity.
We will present the results in a summary receiver operat-
ing characteristic (ROC) curve, summary sensitivity and
specificity, 95 % confidence region around the summary
estimates, and 95 % confidence region.
If there is evidence of threshold effect, then we will esti-
mate summary ROC curves using the hierarchical SROC
(HSROC) model of Rutter and Gatsonis (Rutter [35])
which will allow study level covariates to be added in the
model. In such cases, we will present the results in a
summary ROC curve. From the summary ROC curve,
the expected sensitivity at a given value of specificity
(or vice versa) can be computed [34]. We will compare
index tests against each other using one of the two ap-
proaches (depending on the available data) suggested by
the Cochrane Handbook for Diagnostic Test Accuracy
Reviews [34].
Both the bivariate model and HSROC model can be
used to investigate the relative accuracy of two index
tests depending on the nature of the available data
(common or variable threshold). We will run both the
hierarchical models in SAS software according to the
methods of Macaskill et al. as described in the Cochrane
Handbook for Diagnostic Test Accuracy Reviews [34]. If
the data allow, we will perform sensitivity analysis
based on risk of bias (e.g., treating “unclear risk of bias”
as “low risk” and “high risk,” and removing “high risk
of bias” studies from the analyses) or other PICO elements
(previous procedure in operating room, anesthetic man-
agement, postoperative risk factors prior to discharge, and
postdischarge factors, e.g., dental work). We will conduct
subgroup analyses for the following subgroups:1- Patients undergoing primary arthroplasty
2- Patients undergoing revision arthroplasty
3- Various gold standards used in the included studies
4- Study design, e.g., randomized controlled trials,
observational studies
5- Specific affected joint: shoulder, hip, and knee
6- Time since prosthesis implantation: acute versus
chronic PJI
7- Reasons for arthroplasty, e.g., septic and asepticDiscussion
Total replacements for the hip, knee, and shoulder joints
have proven to be highly successful and cost-effective for
alleviating pain and improving function in patients with
disabling joint disease. However, developing a peripros-
thetic joint infection (PJI) after a total joint replacement
(TJR) is currently one of the most serious and challenging
complications that face our patients and their families, cli-
nicians, and our healthcare system at large. Diagnosing PJI
has remained challenging due to the lack of a gold stand-
ard, which makes it difficult to diagnose and treat patients
in a timely fashion. This affects patients’ quality of life, en-
hances suffering, results in poor outcomes, and increases
the economic burden on the healthcare system. None of
the existing clinical guidelines on diagnosing PJI is based
on a systematic review of all available evidence [2–5].
In 2014, over 100,000 primary hip and knee replacement
were performed in Canada according to the Canadian Joint
Replacement Registry. This translates into a 5-year increase
of over 15 %. The annual incidence increase is estimated to
be over 200 cases, most due to Canada’s growing geriatric
population [36]. Considering this prediction, we need
to urgently develop strategies in order to establish a
timely and accurate diagnosis of PJI.
We believe that a higher quality of scientific rigor is
necessary to establish a diagnostic guideline that represents
current evidence more accurately relative to guidelines
based on consensus, expert opinions, and narrative re-
views. Therefore, we will conduct a systemic review of
diagnostic testing (blood markers, synovial fluids, and
tissue testing) for PJI using appropriate methodologies
and quality assessment tools that may feed into an
evidence-based clinical practice guideline.
The limitations of previous clinical guidelines include
their being based on consensus, expert opinion, and nar-
rative reviews. Additionally, the use of gold standard has
been inconsistent throughout the literature and other
guidelines.
The strength of this evidence lies in its status as a sys-
tematic literature search, its coverage of three major joints
(hip, knee, and shoulder), and the fact that it will be
guided by knowledge users (an orthopedist and infectious
disease specialists).
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the diagnostic performance of various tests, with those
provided by other consensus-based guidelines, and we
will discuss the differences and similarities in point esti-
mates. This systematic review will constitute a foundation
for evidence-based guides on diagnostic performance of
blood markers, synovial fluid tests, and tissue cultures;
these guides will provide recommendations to clinicians
and surgeons for diagnosing PJI accurately and efficiently.
Currently, there are no clear clinical pathways to diagnose
PJI, and available consensus-based guidelines lack the evi-
dence of indicating how these tests should be triaged and
added on or used to replace an existing test. This system-
atic review can help address this gap and may also identify
knowledge gaps in PJI diagnosis that could direct further
research in the field.Additional files
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Additional file 2: Search strategy for periprosthetic joint infection
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in order to tailor the tool based on our research question.
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